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Abstract: The aims of this study were to determine whether combination chemotherapeutics
exhibit a synergistic effect on breast cancer cell metabolism. Palbociclib, is a selective inhibitor
of cyclin-dependent kinases 4 and 6, and when patients are treated in combination with fulvestrant, an
estrogen receptor antagonist, they have improved progression-free survival. The mechanisms for this
survival advantage are not known. Therefore, we analyzed metabolic and transcriptomic changes in
MCF-7 cells following single and combination chemotherapy to determine whether selective metabolic
pathways are targeted during these different modes of treatment. Individually, the drugs caused
metabolic disruption to the same metabolic pathways, however fulvestrant additionally attenuated the
pentose phosphate pathway and the production of important coenzymes. A comprehensive effect was
observed when the drugs were applied together, confirming the combinatory therapy’s synergism in
the cell model. This study also highlights the power of merging high-dimensional datasets to unravel
mechanisms involved in cancer metabolism and therapy.
Keywords: combination drug therapy; breast cancer; multi-omics; metabolomics; RNA-seq;
XCMS Online
1. Introduction
Cell cycle regulation is frequently disrupted in breast cancer [1,2]. Cyclin-dependent kinases
(CDKs) control this regulation enabling quiescent cells to enter the G1-phase and transition to the
S phase. CDKs 4 and 6 phosphorylate the retinoblastoma (RB) protein enabling the release of E2F
transcription factors (E2Fs) which mediates transition into the S-phase. Mutations to the CDK-RB1-E2F
pathway typically result in the amplification of CCND1 which encodes cyclin D1. Both are correlated
with estrogen receptor positive (ER+) breast cancers. Thus, the re-establishment of normal cell cycle
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control through the inhibition of CDKs is an interesting option for the development of targeted cancer
therapy. In recent years, agents have been developed which selectively target CDK4/6 [2].
The development of CDK4/6 inhibitors such as palbociclib (Ibrance®, PD0332991) target
the adenosine triphosphate (ATP) binding site of CDK4-cyclin D and CDK6-cyclin D complexes.
This induces cell cycle arrest in the G1-phase [3]. Palbociclib is a selective, small-molecule inhibitor
of CDK4/6 with the ability to block RB phosphorylation. It can be taken in combination with
either the aromatase inhibitor letrozole, or the ER antagonist fulvestrant. Letrozole is used as
an initial endocrine-based therapy in post-menopausal women with ER+, human epidermal growth
factor receptor 2 (HER2) negative metastatic breast cancer [4,5]. An accelerated U.S. food and
drug administration (FDA) approval for this combined therapy was granted in February 2015.
This was based on a randomized phase 2 study of 165 post-menopausal women, which showed
a progression-free survival (PFS) rate of about 20.2 months when patients were treated with palbociclib
and letrozole, compared to a PFS rate of 10.2 months among those treated with letrozole alone [6].
In early 2016, the FDA approval for palbociclib was expanded to include combined therapy with
fulvestrant, based on a phase 3 study [7]. The median PFS of 3.8 months (placebo/fulvestrant) was
increased to 9.2 months for palbociclib/fulvestrant [7]. This combined treatment is currently in
use for women with disease progression following hormonal therapy and can also be applied to
pre-menopausal women [8].
In vitro studies have demonstrated the sensitivity of palbociclib towards different breast cancer
cell lines and showed a synergistic effect with tamoxifen and trastuzumab in ER+ and HER2-amplified
cell lines, respectively [9]. In addition, a previous study investigated the effect of calcein
acetoxymethyl-ester (a potent inhibitor of CDK4/6) on cancer cell metabolism, revealing an associated
decrease in the concentration of sugar phosphates. This results in an imbalance of the pentose
phosphate pathway (PPP) towards the non-oxidative branch versus the oxidative in human colon
adenocarcinoma cells, and a state of metabolic inefficiency hypothesized to halt cell proliferation [10].
We also recently employed metabolomics to investigate the effect of palbociclib and letrozole used in
single and combination doses in MCF-7 cells. We determined that the combined effects of palbociclib
and letrozole on cellular metabolism had a more profound effect than each agent alone, with enhanced
changes seen in metabolites in nucleotide metabolism, amino acids, and central carbon metabolism [11].
Therefore, the aims of our study were to determine whether the combined effects of palbociclib
and fulvestrant also exert a synergistic effect on breast cancer cell metabolism, and help understand
the mechanism underlying the increase in PFS for patients undergoing combined CDK4/6 inhibitor
and endocrine therapies. We integrated metabolomic and transcriptomic data using XCMS Online to
provide a multi-omic view of dysregulated metabolic pathways [12]. This revealed the response of
both metabolites and genes to each drug, and the combined effect of attenuating multiple pathways
arresting cell growth.
2. Results and Discussion
2.1. Metabolomics Analysis
To identify metabolic pathways modulated by the drugs, MCF-7 breast cancer cells (which are
ER+) were dosed with either vehicle (control), palbociclib, fulvestrant, or a combination dose containing
both drugs (Figure 1). Cells were harvested two and seven days post-dose, with another set harvested
after seven days post-dose, with re-feeding on day four. This design allowed for the evaluation of short-
and long-term responses to drug treatment. Untargeted mass spectrometry-based metabolomics was
carried out on the cell lysates to analyze intracellular metabolites and the obtained data evaluated using
the XCMS Online platform https://xcmsonline.scripps.edu [12–14]. The data revealed that metabolites
in control samples (vehicle) changed in abundance over time due to expected cancer cell proliferation.
This can be seen in Figure 2 which shows the relative abundances of guanosine monophosphate,
sedoheptulose-7-phosphate, and oxidized nicotinamide adenine dinucleotide changing over time.
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Therefore, meta-analyses were used for further data evaluation, comparing altered metabolites
from each drug treatment normalized to controls [15]. The putatively identified metabolites from
those experiments were subsequently mapped onto metabolic pathways using mummichog analysis
housed on XCMS Online [12,16]. Metabolite identities were confirmed by comparing MS/MS spectra
with authentic reference standards, and quantified by targeted multiple reaction monitoring mass
spectrometry, which provided additional validation.
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The results indicated that two days after a simultaneous dose of both drugs (palbociclib and
fulvestrant) metabolites were dysregulated in multiple metabolic pathways in central carbon
metabolism: The tricarboxylic acid (TCA) cycle, PPP, and purine synthesis. Figure 3 illustrates the
changes to these pathways on single and combination dosing. In the TCA cycle, succinate was increased
1.9-fold, and fumarate and malate were decreased 2.0-fold and 34.0-fold respectively. This indicates
a blockade of succi ate metabolism possibly through inhibition of succinate dehydrogenase (SDH).
Mutations to SDH have been s en in multiple cancers, with elevated succinate levels observed in
cancer patients [17]. SDH requires FAD+ and NAD+ as co-factors [18], NAD+ was not decreased
after two days of dosing, suggesting that other factors may be involved in SDH inhibition, such as
tumor necrosis factor receptor-associated protein 1 (TRAP1). TRAP1 inhibits respiratory complex
II downregulating SDH causing high concentrations of succinate [19]. This effect was also evident
in single agent dosing of both drugs but to a lesser degree; malate was only decreased 4.0 and
3.5-fold when treated with palbociclib and fulvestrant alone respectively. Metabolites in both
the oxidative d no -oxidative phases of the PPP were downregulated y combination dosing;
sedoheptulose-7-phosphate (3.7-fold) and 6-phosphogluconat (2.5- o d). These m tabolit s were also
down- gulated by fulvestrant dosing alone to a similar xtent but were unaffected by palbociclib,
therefore it appears that the combination drug dosing effects on the PPP are driven by fulvestrant
alone. Furthermore, three additional metabolites with roles in central carbon metabolism, were altered
after combination dosing but were not changed with any single agent dosing; N-acetylglucosamine
phosphate (1.2-fold increase), inosine monophosphate (16-fold decrease), and fructose-1-phosphate
(2.8-fold decrease) (Table S1). Given the changes observed to metabolites in PPP, purine synthesis, and
TCA cycle intermediates after two days of dosing, it appears that these drugs act in synergy to target
the same pathways that are important to ell growth and survival, as well a having s parate actions
on distinct pathways. This combinatorial effect enables a wider network of pathways to be modulated,
thereby preventing the production of macromolecules and energy required for cancer cell growth and
increasing senescence. A list of all significant metabolite changes after two days is illustrated in Table 1.
At seven days post-dose of single and combination doses, changes to the metabolome were even
more widespread than after two days. However, we first examined the effect of re-feeding the cells at
day four to determine if the observed changes were due to nutrient depletion. It was seen that after
refeeding, three metabolites were no longer dysregulated (malate, arginine, inosine monophosphate),
therefore they were not altered because of drug efficacy and increased senescence (Figure 4, Table S1).
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Table 1. Panel of significantly altered metabolites 2 days after dosing with palbociclib (n = 4), fulvestrant
(n = 4) or a combination dose of both palbociclib and fulvestrant (n = 4) when comparing dosed groups
to control. Values are log transformed fold changes after quantification by multiple reaction monitoring,
unpaired two-tailed t-test.
Metabolite Name
Palbociclib Fulvestrant Combination
Fold Change p-Value Fold Change p-Value Fold Change p-Value
Succinate 1.6 0.0025 1.8 0.0441 1.9 0.0021
Malate −4.0 0.0170 −3.5 0.0381 −34.0 0.0002
Fumarate −2.1 0.0189 −2.1 0.0438 −2.0 0.0003
Phosphoenolpyruvate 1.1 0.0450 N.S N.S 1.2 0.0014
6-phosphogluconate N.S N.S −3.7 0.0255 −2.5 0.0496
Sedoheptulose-7-phosphate N.S N.S −3.6 0.0335 −3.7 0.0003
Serine N.S N.S 1.7 <0.0001 N.S N.S
Cholesterol sulfate N.S N.S −5.2 0.0332 N.S N.S
Taurine N.S N.S −2.1 0.0380 N.S N.S
Inosine monophosphate N.S N.S N.S N.S −16.1 0.0052
Fructose-1-phosphate N.S N.S N.S N.S −2.8 0.0172
There were however a number of metabolites that were changed after seven days of dosing
and not affected by refeeding, as can be seen in Table S1. In contrast to the metabolic changes
observed at day two post-dose, some of the metabolite concentrations were now changed in the
opposite direction. For example, succinate decreased with both fulvestrant alone and combination
dosing, however fumarate was not changed. This could be a result of decreased citrate/isocitrate
utilization in the TCA cycle due to a now depleted NAD+; of note citrate/isocitrate were increased
under all dosing conditions at seven days, which supports this hypothesis. Decreased citrate/citrate
utilization in the TCA cycle would lead to lower levels of succinate. Succinate is known to upregulate
TRAP1, therefore decreased succinate accumulation may impact SDH via decreased TRAP1 expression.
Furthermore, deletion of TRAP1 has been shown to inhibit tumor growth in MCF-7 cells [20].
An additional change from two to seven days post-dose was seen in metabolites housed in the PPP;
the intermediate sedoheptulose-7-phosphate was increased after fulvestrant and combination dosing.
Fructose-1-phosphate was similarly changed, this metabolite can feed into the glycolytic pathway to
produce glyceraldehyde and dihydroxyacetone phosphate, however additional changes to metabolites
in the glycolysis pathway were not observed (or could not be measured) at seven days compared to
controls. The depletion of serine (fulvestrant and combination) and tyrosine (palbociclib, fulvestrant,
and combination), and an increase in phosphoenolpyruvate (palbociclib only) indicate that isoform
M2 of pyruvate kinase (PKM2) regulation could be affected by the actions of palbociclib in single
and combination doses [21]. At seven days post-dose, metabolite flow into the TCA cycle changed
dramatically with an accompanying decrease in amino acids (aspartate, serine, proline, asparagine,
tryptophan, tyrosine), NAD+ and NADP+ (Figure 5, Table 2). All these actions were driven by
fulvestrant and could lead to increased oxidative stress in the cell thus causing cell death [22].
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Figure 5. Overview of metabolite changes occurring in MCF-7 breast cancer cells. Seven days post
palbociclib and fulvestrant, single and combination dosing.
Taken together the results at seven days after combination dosing of palbociclib and fulvestrant
show that the drugs act to inhibit purine, amino acid and important coenzyme synthesis. They also
modulate glycolytic, TCA cycle and PPP metabolism possibly affecting the regulation of key enzymes
such as PKM2 and SDH. An overview of metabolite changes after seven days with re-feeding is shown
in Figure 5 and Table 2.
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Table 2. Panel of significantly altered metabolites 7 days after dosing with palbociclib (n = 4), fulvestrant
(n = 4), or a combination dose of both palbociclib and fulvestrant (n = 4) when comparing dosed groups
to control. Values are log transformed fold changes after quantification by multiple reaction monitoring,
unpaired two-tailed t-test.
Metabolite Name
Palbociclib Fulvestrant Combination
Fold Change p-Value Fold Change p-Value Fold Change p-Value
Sedoheptulose-7-phosphate 3.5 0.0076 13.2 <0.0001 6.4 0.0012
NADP N.S N.S −2.6 0.0168 −3.7 0.0030
Citrate/Isocitrate 9.3 <0.0001 5.3 <0.0001 3.8 0.0017
Succinate −1.9 0.0047 −1.7 <0.0001 −1.8 0.0356
Malate 2.4 0.0130 N.S N.S 1.7 0.0323
Fructose-1-phosphate 5.8 0.0036 19.5 0.0002 11.2 0.0006
N-acetylaspartylglutamate N.S N.S −3.4 0.0030 −2.6 0.0051
Aspartate N.S N.S −2.6 0.0021 −2.3 0.0041
Serine N.S N.S −2.7 0.0370 −3.2 0.0245
Proline N.S N.S N.S N.S −2.5 0.0014
Asparagine N.S N.S −5.5 0.0021 −8.4 0.0003
Tryptophan N.S N.S N.S N.S −2.9 0.0134
Tyrosine −10.0 0.0138 −1008.1 <0.0001 −696.5 <0.0001
Phenylalanine N.S N.S 4.2 0.0007 3.5 0.0008
Valine 1.8 0.0050 1.5 0.0003 1.7 <0.0001
Arginine N.S N.S N.S N.S −3.5 0.0174
Guanosine −1.3 0.0496 N.S N.S −4.5 <0.0001
Inosine monophosphate −33.3 <0.0001 −37.3 0.0032 −29.2 0.0021
Adenosine monophosphate −8.5 0.0008 −11.1 0.0017 −10.9 0.0019
2.2. Transcriptomics Analysis
In addition to comprehensive metabolomic analysis, RNA sequencing was performed to
determine gene expression changes relating to single agent or combination drug dosing. Cells were
collected at various time points (one day and seven days after dosing, with an additional time point
at ten days with re-dosing at day seven). Metabolic genes appear highly over-represented among
those whose expression were modulated by palbociclib as well as its combination with fulvestrant
(Figure S1; Table S2). Gene set enrichment analysis [23,24] further identified significantly impacted
metabolic pathways (Table S3) including metabolism of drug, nucleotides (both pyrimidine and purine;
Figure S2), amino acids (histidine, phenylalanine and glycine/serine/threonine), fatty acids and retinol.
The differential regulation of selected genes after palbociclib, fulvestrant, or combination treatment
dosing compared to the control, can be seen on Figure 6 and Table S2.
To correlate our metabolite changes with gene expression changes, we used the recently
developed systems biology, omic data integration tool on XCMS Online [12]. This tool identified
four metabolic pathways which had both metabolite and gene involvement during combination
dosing. These pathways are all associated with purine biosynthesis and degradation (Table 3). The two
main genes identified in these metabolic pathways were phosphoribosylaminoimidazole carboxylase
(PAICS) and purine nucleoside phosphorylase (PNP) which were both highly downregulated at all
time points (Table S2). This confirms that combination dosing affects the biosynthesis of purine
nucleotides. However, due to multiple single nucleotide polymorphisms that exist for both PAICS and
PNP, interindividual variability in response to combination dosing may be seen in human populations.
Other metabolic pathways altered by combination dosing were not identified at the gene level,
suggesting the presence of a lag phase between gene-protein-metabolite expression or the insurgence
of regulatory mechanisms directly operating at metabolite-protein level.
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dosing, one day (1D), seven days (7D) and ten days (10D) post-dose: (a) heatmap of dysregulated genes
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Table 3. Active pathways mapped using untargeted metabolite and RNA-seq data at seven days post
combination dose by XMCS Online. Pathway names provided by BioCyc Database Collection [25].
Pathway Genes Metabolites
Number/All %Overlap Number/All %Overlap
Adenosine nucleotides degradation II 1/5 20 3/10 30.0
Guanosine nucleotides degradation III 1/3 33.3 2/9 22.2
Urate biosynthesis/inosine
5’-phosphate degradation 1/2 50.0 1/8 8.3
Inosin 5’-phosphate biosynthesis II 1/5 20.0 1/12 N/A
2.3. Comparison with Previous Results
Metabolomics analysis was previously conducted to characterize breast cancer cell line responses
to clinical drugs such as the taxane-based chemotherapeutic paclitaxel [26]. Several metabolites such as
aspartate, citrate, glutamate, pyroglutamate, myo-Inositol, UDP-glucuronate, and O-phosphocholine
were increased in MCF-7 cells that were treated with paclitaxel. While branched chain amino acids
such as leucine, isoleucine, and valine were reduced with paclitaxel treatment, metabolites i the
glycolysis pathway, such as glucose and lactate were also decreased, which indicates a reduction in
glycolysis with drug treatment. However, previous work focusing on single dr g treatment and the
response of combination therapy is sparse.
We previously identified enhanced disruption to nucleotide metabolism, amino acids, and PPP
i termediates upo a two-day combination therapy with palbociclib and letrozole. Similar to the
single treatment with palbociclib, minor changes were seen to cell metabolis ; slight ecreases in
malate, no changes to amino acids and the majority of central carbon metabolites. Single treatments
with letrozole and fulvestrant appeared to have different effects on MCF-7 cells, underscoring their
different endocrine mechanisms; fulvestrant is a selective ER inhibitor, whereas letrozole inhibits
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estrogen biosynthesis. The metabolites with the strongest response to fulvestrant after two days of
dosing were sedoheptulose-7-phosphate, serine, 6-phosphogluconate, fumarate, malate, succinate,
cholesterol sulfate, and taurine. Whereas, only slight metabolic responses were seen with letrozole,
with changes to 5-phosphogluconic acid, uridine, and metabolites in the glycolysis pathway.
Combination dosing with letrozole saw decreases in amino acids at two days, which were
only apparent with fulvestrant at seven days post-dose. The major difference between the two
treatments was the effect on nucleotide metabolism. In the case of fulvestrant combination dosing,
we saw decreases in nucleotides, whereas with letrozole, increases were seen after two days of
dosing, however it is not clear at this point whether a longer dosing time would result in similar
effects. Thus, comparing these treatments show that combination therapies, which include a CDK 4/6
inhibitor and endocrine therapy, have a more profound effect on breast cancer cell metabolism.
3. Materials and Methods
3.1. Cell Culture
MCF-7 breast cancer cells (ATCC, Manassas, VA, USA) were cultured in RPMI 1640 medium
(Gibco-Life Tech, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Sigma, St. Louis,
MO, USA) and penicillin-streptomycin (Gibco-Life Tech, Grand Island, NY, USA) at 37 ◦C and 5%
CO2. Cells were passaged routinely at a ratio of 1:3 or 1:4 every 3–4 days using trypsin/EDTA.
For metabolomics experiments, cells were seeded into 150 mm cell culture dishes (Corning, NY, USA)
and treated with either palbociclib (200 nM), fulvestrant (10 nM), a combination of those, or the
vehicle as control. Four replicates were generated per experiment (approximately 3–5 million cells
per replicate). Cells were harvested after two and seven days. Additionally, cells were taken after day
seven with a refresh of the medium containing the respective drug(s) after day four. In total, there were
n = 4/drug treatment groups at two, seven, and seven days with refeeding, resulting in a total number
of 48 biological samples for metabolomics analysis.
3.2. Sample Preparation for Metabolomics Experiments
Prior to the sample harvest, cells were washed twice with phosphate buffer solution
(Gibco-Life Tech, Grand Island, NY, USA) and 500 µL water was added to the culture dish. The bottom
of the culture dish was flash-dipped into liquid nitrogen to quench metabolism immediately and cells
were harvested using a cell scraper. Cell suspensions were transferred to 1.5 mL Eppendorf tubes
and further processed with three freeze-thaw cycles (1 min freezing, 5 min thawing) on wet ice using
liquid nitrogen and 10 min of sonication in an ice water bath. Samples were centrifuged for 10 min at
13,000 rpm and 4 ◦C. Supernatants were collected and protein concentration was quantified using a
Pierce Micro BCA protein assay kit (Pierce, Rockford, IL, USA). Lysed samples were further extracted
in acetonitrile/methanol/lysate (2:2:1 v/v/v). Tubes were then vortexed for 30 s in 1.5 mL Eppendorf
tubes, sonicated for 10 min and stored at −20 ◦C for 1 h. Samples were subsequently centrifuged for
15 min at 13,000 rpm and 4 ◦C. Supernatants were transferred to 1.5 mL high recovery glass autosampler
vials (Agilent Technologies, Santa Clara, CA, USA) and dried in a speedvac (Labconco, Kansas City,
MO, USA). According to the protein concentration, the samples were resuspended in acetonitrile/water
(50/50 v/v), where the lowest protein concentration was re-suspended in 100 µL, and all other samples
were relatively adjusted thereafter. Samples were stored at −80 ◦C until analysis.
3.3. Untargeted Metabolomics Analysis
Analyses were performed using a high performance liquid chromatography (HPLC) system
(1200 series, Agilent Technologies, Santa Clara, CA, USA) coupled with an electrospray ionization
(ESI) source and a 6550 ion funnel quadrupole time-of-flight (Q-TOF) mass spectrometer
(Agilent Technologies, Santa Clara, CA, USA). Samples were injected (8 µL) onto a Luna aminopropyl,
3 µm, 150 mm × 1.0 mm I.D. column (Phenomenex, Torrance, CA, USA) for HILIC analysis in
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ESI negative mode. HILIC was chosen to analyze predominantly central carbon metabolites as
they are typically retained better by HILIC stationary phases upon comparison with reversed phase
columns. Pooled samples were injected after three experimental samples, whereas one solvent blank
was injected after every sample for QC. Mobile phase was A = 20 mM ammonium acetate and
40 mM ammonium hydroxide in 95% water, 5% acetonitrile and B = 95% acetonitrile, 5% water.
The linear gradient elution from 100% B (0–5 min) to 100% A (50–55 min) was applied in HILIC at
a flow rate of 50 µL/min. To ensure column re-equilibration and maintain reproducibility, a 10 min
post-run was applied. ESI source conditions were set as follows: gas temperature 200 ◦C, drying gas
11 L/min, nebulizer 15 psi, fragmentor 365 V, sheath gas temperature 300 ◦C, sheath gas flow 9 L/min,
nozzle voltage 500 V, and capillary voltage 2500 V. The instrument was set to acquire over a m/z
range from 60–1000 with the MS acquisition rate of 1.67 spectra/s. For the acquisition of MS/MS
spectra of selected precursors the default isolation width was set to narrow (1.3 Da), with a MS
acquisition rate at 1.67 spectra/s and MS/MS acquisition at 1.67 spectra/s. The collision energy was
set to 20 eV. Data was processed using XCMS Online [27] with a p-value of < 0.05 and q-value of < 0.1
set as statistical significance threshold cut-offs. Features were listed in a feature list table and as an
interactive cloud plot, containing their integrated intensities (extracted ion chromatographic peak
areas), observed fold changes across the sample groups, and statistical significance for each sample.
3.4. Targeted Metabolomics Analysis
For targeted analysis, a volume of 2 µL was injected onto a Luna aminopropyl, 3 µm,
150 mm × 2.0 mm I.D. column (Phenomenex, Torrance, CA, USA) using an Agilent Technologies
series 1290 Infinity HPLC system with a gradient mobile phase of A = 20 mM ammonium acetate and
40 mM ammonium hydroxide in 95% water, 5% acetonitrile and B = 95% acetonitrile, 5% water.
The linear gradient elution from 95% B (0–2 min) to 10% B for 13 min, then to 0% B in 2 min,
held at 0% B for 3 min, and equilibrated back to 95% B over 4 min at a flow rate of 350 µL/min.
The quantification of metabolites was performed by dynamic multiple reaction monitoring triple
quadrupole mass spectrometry (Agilent Ion-Funnel 6490, Santa Clara, CA, USA). The ESI source
conditions were as follows: Gas temperature 225 ◦C, gas flow 15 L/min, nebulizer 35 psi, sheath gas
400 ◦C, sheath gas flow 12 L/min, capillary voltage 2500 V (ESI negative) or 3500 V (ESI positive) and
nozzle voltage 0 V. The cycle time was set to 500 ms. The collision energies, quantifier and qualifier
ion transitions were optimized for each metabolite using MassHunter Optimizer software and are
reported in the supplementary Table S1. To ensure accurate quantification, external calibration with
standard compound mixtures was performed. Agilent QQQ Quantitative Analysis software was used
to calculate the absolute concentrations of the metabolites in the samples.
3.5. Transcriptome Analysis
MCF-7 breast cancer cells were grown as above and collected at various time points (one day
and seven days after dosing, with an additional time point at ten days with re-dosing at day seven),
n = 3/group. Whole transcriptome RNA sequencing was performed by Biomiga (San Diego, CA, USA).
Each treatment and time point combination was profiled in biological duplicates. The 50 bp paired end
reads were mapped by bowtie2 [28] and quantified using RSEM package [29]. Differential expression
statistics was determined with EdgeR algorithm [30] from expected counts. Gene set enrichment
analysis [31] was performed using TPM values based on weighted signal-to-noise metric and false
discovery rate (FDR) was assessed from 1000 permutations. Gene expression profiles cluster analysis
was performed by average linkage with the Euclidean distance measurement method. Pathway gene
signatures were prepared by mapping gene pathway list from KEGG database [23,24] to Entrez gene
IDs at Pfizer.
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3.6. Statistical Analysis
GraphPad Prism v 6.00 (GraphPad Software, Inc., San Diego, CA, USA) was used for
statistical analysis. The quantitative triple quadrupole data was log transformed and expressed
as mean ± standard error of the mean (S.E.M) after two-tailed t-tests were carried out. Comparisons
with p < 0.05 were assigned to be statistically significant and noted on each graph.
4. Conclusions
To advance the understanding of single versus combination drug therapeutics on cancer cell
metabolism, we used meta-analyses and a novel multi-omics technology to correlate metabolites and
genes to decipher dysregulated metabolic pathways. This tool, which is freely available on XCMS
Online, revealed several pathways significantly modified by palbociclib, fulvestrant, or a combination
of the two. We observed that individually, palbociclib and fulvestrant caused disruption to shared
metabolic pathways, however only fulvestrant acts on the PPP and has a more profound effect on amino
acid biosynthesis. The combined effect of dosing with both drugs enables a comprehensive attenuation
of metabolic pathways involved in co-enzyme production, energy metabolism, and macromolecule
biosynthesis. This confirms that there is an enhanced effect of combined breast cancer therapy over
single treatment, which was reported recently in a phase 3 study in vivo [7]. Interestingly, after seven
days post-treatment, we observed the initiation of a salvage mechanism, whereby the glycolytic
pathway is shunted towards the PPP, indicating that the cells may be attempting to synthesize serine
and purines through an alternative mechanism. Thus, future studies should be designed to investigate
the adaptive mechanisms of the cancer cells after removal of the drugs.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-1989/9/1/7/s1,
Figure S1: The enrichment of metabolic genes among those modulated by drug treatments, Figure S2: GSEA
enrichment plot of pyrimidine metabolism and purine metabolism (FDR q = 4.92E−5 and 3.83E−2), 24 h combo
treatment, Table S1: Metabolites observed after treatment of MCF-7 cells with either palbociclib (n = 4), fulvestrant
(n = 4) or a combination dose of both palbociclib and fulvestrant (n = 4), Table S2: Differentially expressed metabolic
genes from drug treatments (FDR≤ 0.01 and FC≥ 2), Table S3: Transcriptome-based gene set enrichment analysis
result of the KEGG metabolism-related pathways, significant in at least one of the samples (False Discovery Rate < 0.05).
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